Uroken 500000IU Injection

Introduction

Uroken is a medication that contains the active ingredient Urokinase. It is available in the form of an injection and is prescribed by healthcare professionals for specific medical conditions.

Uses

Uroken is primarily used for the treatment of blood clots in the body. It is commonly prescribed for conditions such as deep vein thrombosis (DVT), pulmonary embolism (PE), and arterial thrombosis. It works by dissolving the blood clots, thereby improving blood flow and preventing further complications.

Dosage and Administration

The dosage and administration of Uroken should be determined by a healthcare professional based on individual patient factors, including the severity of the condition and the patient’s response to treatment. It is typically administered by a healthcare professional in a hospital or clinical setting. The medication is injected directly into a vein (intravenous infusion) over a certain period of time. The exact dosage and duration of treatment will be determined by your healthcare provider.

Mechanism of Action

Urokinase, the active ingredient in Uroken, is a type of enzyme that works by breaking down and dissolving blood clots. It specifically targets the fibrin component of blood clots, leading to their breakdown and restoration of blood flow. By restoring blood flow, Uroken helps to prevent further complications associated with blood clots.

Side Effects

Common side effects may include fever, chills, headache, nausea, vomiting, and bleeding at the injection site. These side effects are usually mild and temporary.

However, in rare cases, Uroken can cause serious side effects. These may include severe bleeding, allergic reactions, or other serious medical conditions. If you experience any unusual or severe side effects, seek immediate medical attention.

Drug Interactions

Uroken may interact with certain medications, including anticoagulants (blood thinners), antiplatelet drugs, and other medications that affect blood clotting. Inform your healthcare provider about all the medications you are currently taking, including prescription, over-the-counter, and herbal products. They can help determine if any potential drug interactions may occur and adjust your treatment plan accordingly.

Precautions

Before using Uroken, inform your healthcare provider about any medical conditions you have, including a history of bleeding disorders, recent surgery, or any other underlying health conditions. Additionally, let your healthcare provider know if you are pregnant, planning to become pregnant, or breastfeeding, as the use of Uroken may need to be adjusted in these situations.

Uroken should not be used in individuals who are allergic to Urokinase or any of its components. Follow your healthcare provider’s instructions and precautions to ensure safe and effective use of this medication.

Storage

Uroken should be stored in a cool, dry place at a temperature between 2°C and 8°C (36°F and 46°F). It should be protected from light and kept out of the reach of children. Do not freeze the medication, and discard any unused portion according to the instructions provided by your healthcare provider or pharmacist.

Patient Tips

• Follow the dosage and administration instructions provided by your healthcare provider.
• If you miss a dose, contact your healthcare provider for further instructions.
• Inform your healthcare provider if you experience any unusual or severe side effects.
• Avoid activities that may increase your risk of injury or bleeding while using Uroken.
• Keep all follow-up appointments with your healthcare provider to monitor your progress and response to treatment.

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

• Syner-KINASE 10,000 IU powder for solution for injection/infusion (Health Professionals SmPC) Available at:
• Urokinase (Drugs.com) [Accessed 28 Jun. 2024] (online) Available at:
• Thrombolytic therapy (MedlinePlus) [Accessed 7 Jun. 2024] (online) Available at:
• Crippa MP. Urokinase-type plasminogen activator. Int J Biochem Cell Biol. 2007;39(4):690-4. doi: 10.1016/j.biocel.2006.10.008. Epub 2006 Oct 21. [Accessed 3 Jun. 2024] Available at: